Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Patients

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following
criteria:

- No radiographic evidence of disease

- Stable disease, defined as no tumor progression within the past 3 months

- Previously treated with 1 course of localized or whole brain radiotherapy of at least
3,000 cGy at least 6 months before study registration

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- Karnofsky 70-100%

Life expectancy

- At least 30 weeks

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Other

- Not pregnant or nursing

- Negative pregnancy test

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- No concurrent chemotherapy

Endocrine therapy

- Concurrent steroid therapy allowed if on stable or decreasing dose

Radiotherapy

- See Disease Characteristics

- No concurrent cranial radiotherapy

Surgery

- No concurrent surgery

Other

- More than 3 months since prior donepezil or EGb761

- No concurrent donepezil (group 2 only)

- No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03)

- No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or
enoxaparin) (group 2 only)

- No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine)

- No other concurrent therapy